Status:
UNKNOWN
Possible Differences in HCC Course Depending on DAA Treatment
Lead Sponsor:
Medical University of Warsaw
Conditions:
Carcinoma, Hepatocellular
Hepatitis C Virus Infection, Response to Therapy of
Eligibility:
All Genders
18-90 years
Brief Summary
BACKGROUND It is estimated that around 71 milion people live with chronic hepatitis C virus (HCV) infection. This may lead to the development of liver cirrhosis and hepatocellular carcinoma (HCC). Liv...
Eligibility Criteria
Inclusion
- hepatocellular carcinoma diagnosis
- age \>18 years old
Exclusion
- age \<18 years old
Key Trial Info
Start Date :
May 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05376943
Start Date
May 10 2022
End Date
December 1 2022
Last Update
May 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Warsaw
Warsaw, Masovian Voivodeship, Poland, 02-091